JP2002030084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002030084A5 JP2002030084A5 JP2000217709A JP2000217709A JP2002030084A5 JP 2002030084 A5 JP2002030084 A5 JP 2002030084A5 JP 2000217709 A JP2000217709 A JP 2000217709A JP 2000217709 A JP2000217709 A JP 2000217709A JP 2002030084 A5 JP2002030084 A5 JP 2002030084A5
- Authority
- JP
- Japan
- Prior art keywords
- benzo
- azabicyclo
- thiophen
- octane
- azabicycloalkane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 12
- 230000003287 optical effect Effects 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- RHJDMHSBBRFVQT-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)-1-(1-benzothiophen-2-yl)ethanone Chemical compound C1=CC=C2SC(C(CC3C4CCN(CC4)C3)=O)=CC2=C1 RHJDMHSBBRFVQT-UHFFFAOYSA-N 0.000 description 6
- MBQTZDNDJHEQDS-UHFFFAOYSA-N 3-[2-(1-benzothiophen-2-yl)ethyl]-1-azabicyclo[2.2.2]octane Chemical compound C1N(CC2)CCC2C1CCC1=CC2=CC=CC=C2S1 MBQTZDNDJHEQDS-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- -1 Benzo [b] thiophen-2-yl Chemical group 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- GFYPTKLMKVKMDV-HNNXBMFYSA-N (3r)-3-(1-benzothiophen-2-ylmethoxy)-1-azabicyclo[2.2.2]octane Chemical compound C1=CC=C2SC(CO[C@@H]3C4CCN(CC4)C3)=CC2=C1 GFYPTKLMKVKMDV-HNNXBMFYSA-N 0.000 description 2
- GFYPTKLMKVKMDV-OAHLLOKOSA-N (3s)-3-(1-benzothiophen-2-ylmethoxy)-1-azabicyclo[2.2.2]octane Chemical compound C1=CC=C2SC(CO[C@H]3C4CCN(CC4)C3)=CC2=C1 GFYPTKLMKVKMDV-OAHLLOKOSA-N 0.000 description 2
- SHRLWGYNTYFYTI-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl(1-benzothiophen-2-yl)methanone Chemical compound C1=CC=C2SC(C(C3C4CCN(CC4)C3)=O)=CC2=C1 SHRLWGYNTYFYTI-UHFFFAOYSA-N 0.000 description 2
- ZJJRKBHGYKDFOG-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)-1-(1,3-benzothiazol-2-yl)ethanone Chemical compound C1=CC=C2SC(C(CC3C4CCN(CC4)C3)=O)=NC2=C1 ZJJRKBHGYKDFOG-UHFFFAOYSA-N 0.000 description 2
- FMDNXPDPJHMQEM-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)-1-(1-benzofuran-2-yl)ethanone Chemical compound C1=CC=C2OC(C(CC3C4CCN(CC4)C3)=O)=CC2=C1 FMDNXPDPJHMQEM-UHFFFAOYSA-N 0.000 description 2
- GFYPTKLMKVKMDV-UHFFFAOYSA-N 3-(1-benzothiophen-2-ylmethoxy)-1-azabicyclo[2.2.2]octane Chemical compound C1=CC=C2SC(COC3C4CCN(CC4)C3)=CC2=C1 GFYPTKLMKVKMDV-UHFFFAOYSA-N 0.000 description 2
- ZOGYPQAMAFELAL-UHFFFAOYSA-N 3-(1-benzothiophen-2-ylmethyl)-1-azabicyclo[2.2.2]octane Chemical compound C1=CC=C2SC(CC3C4CCN(CC4)C3)=CC2=C1 ZOGYPQAMAFELAL-UHFFFAOYSA-N 0.000 description 2
- DLQOQDWFQJABBK-UHFFFAOYSA-N 3-[3-(1-benzothiophen-2-yl)propyl]-1-azabicyclo[2.2.2]octane Chemical compound C1=CC=C2SC(CCCC3C4CCN(CC4)C3)=CC2=C1 DLQOQDWFQJABBK-UHFFFAOYSA-N 0.000 description 2
- LRTRRSAXRXNUKV-UHFFFAOYSA-N CN1C2=CC=CC=C2N=C1C(=O)CC3CN4CCC3CC4 Chemical compound CN1C2=CC=CC=C2N=C1C(=O)CC3CN4CCC3CC4 LRTRRSAXRXNUKV-UHFFFAOYSA-N 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- CDAVRNSZZUNKKJ-UHFFFAOYSA-N 3-(1-azabicyclo[2.2.2]octan-3-yl)-1-(1-benzothiophen-2-yl)propan-1-one Chemical compound C1=CC=C2SC(C(CCC3C4CCN(CC4)C3)=O)=CC2=C1 CDAVRNSZZUNKKJ-UHFFFAOYSA-N 0.000 description 1
- 229940122656 Alpha-7 nicotinic receptor agonist Drugs 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 125000005118 N-alkylcarbamoyl group Chemical group 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229940005524 anti-dementia drug Drugs 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000217709A JP4616971B2 (ja) | 2000-07-18 | 2000-07-18 | １−アザビシクロアルカン化合物およびその医薬用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000217709A JP4616971B2 (ja) | 2000-07-18 | 2000-07-18 | １−アザビシクロアルカン化合物およびその医薬用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002030084A JP2002030084A (ja) | 2002-01-29 |
| JP2002030084A5 true JP2002030084A5 (enExample) | 2010-07-08 |
| JP4616971B2 JP4616971B2 (ja) | 2011-01-19 |
Family
ID=18712778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000217709A Expired - Fee Related JP4616971B2 (ja) | 2000-07-18 | 2000-07-18 | １−アザビシクロアルカン化合物およびその医薬用途 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4616971B2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| NZ531786A (en) | 2001-10-02 | 2006-10-27 | Upjohn Co | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| MXPA04012439A (es) * | 2002-06-10 | 2005-04-19 | Bayer Healthcare Ag | Amidas de acidos 2-heteroarilcarboxilicos. |
| DE10234424A1 (de) | 2002-07-29 | 2004-02-12 | Bayer Ag | Benzothiophen-, Benzofuran- und Indolharnstoffe |
| RU2323217C2 (ru) * | 2002-08-14 | 2008-04-27 | Ньюросерч А/С | Новые хинуклидиновые производные и их применение |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| RU2391341C2 (ru) | 2002-09-25 | 2010-06-10 | Мемори Фармасьютиклз Корпорейшн | Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение |
| EP1581223B2 (en) | 2002-12-06 | 2016-05-25 | The Feinstein Institute for Medical Research | Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists |
| US7238715B2 (en) | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| NZ548228A (en) | 2003-12-22 | 2009-04-30 | Memory Pharm Corp | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
| BRPI0508771A (pt) | 2004-03-25 | 2007-08-14 | Memory Pharm Corp | indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos |
| WO2006001894A1 (en) | 2004-04-22 | 2006-01-05 | Memory Pharmaceutical Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| ATE505470T1 (de) | 2004-05-07 | 2011-04-15 | Memory Pharm Corp | 1h-indazole, benzothiazole, 1,2-benzisoxazole, 1, 2-benzisothiazole und chromone und deren herstellung und verwendungen |
| AR049401A1 (es) | 2004-06-18 | 2006-07-26 | Novartis Ag | Aza-biciclononanos |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| JP2008525464A (ja) | 2004-12-22 | 2008-07-17 | メモリー・ファーマシューティカルズ・コーポレイション | α−７ニコチン性受容体リガンド並びにその製造及び使用 |
| FR2884822B1 (fr) * | 2005-04-22 | 2007-06-29 | Aventis Pharma Sa | Derives de triazines, leur preparation et leur application en therapeutique |
| US8106066B2 (en) | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| ATE509931T1 (de) * | 2007-03-23 | 2011-06-15 | Abbott Lab | Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür |
| PL2540297T3 (pl) | 2008-11-19 | 2015-12-31 | Forum Pharmaceuticals Inc | Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami |
| MX2012013345A (es) | 2010-05-17 | 2013-02-11 | Envivo Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado. |
| EP3461481A1 (en) | 2012-05-08 | 2019-04-03 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5967284A (ja) * | 1982-07-13 | 1984-04-16 | サンド・アクチエンゲルシヤフト | インドリルカルボン酸ピペリジルエステル誘導体 |
| US4910193A (en) * | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
| JP4163263B2 (ja) * | 1995-04-06 | 2008-10-08 | 矢崎総業株式会社 | 防水コネクタ |
-
2000
- 2000-07-18 JP JP2000217709A patent/JP4616971B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002030084A5 (enExample) | ||
| JP2006509749A5 (enExample) | ||
| JP2006514626A5 (enExample) | ||
| JP2007520440A5 (enExample) | ||
| TNSN05165A1 (fr) | Derives de pyrrolopyrimidine | |
| WO2002057252A3 (en) | Heterocyclic sulfonamide inhibitors of beta amyloid production | |
| JP2005519908A5 (enExample) | ||
| JP2008509187A5 (enExample) | ||
| MA27596A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
| JP2006524222A5 (enExample) | ||
| JP2004535436A5 (enExample) | ||
| WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
| JP2006500394A5 (enExample) | ||
| WO2005113537B1 (en) | Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions | |
| RU2000128658A (ru) | Тиенилазолилалкоксиэтанамны, их производные и их применение в качестве лекарственных средств | |
| JP2002527414A5 (enExample) | ||
| JP2003503449A5 (enExample) | ||
| JP2003502367A5 (enExample) | ||
| JP2005538111A5 (enExample) | ||
| JP2005505583A5 (enExample) | ||
| JP2004525184A5 (enExample) | ||
| JP2007507474A5 (enExample) | ||
| JP2003513075A5 (enExample) | ||
| JP2006524682A5 (enExample) | ||
| WO2004064771A3 (en) | Geminally di-substituted nsaid derivatives as abeta 42 lowering agents |